News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Allergan (AGN) Reports Continued Strong Execution In Second Quarter 2017 With 9% Increase In GAAP Net Revenues To $4.0 Billion



8/3/2017 12:39:30 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
DUBLIN, Aug. 3, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its second quarter 2017 continuing operations performance.

Total net revenues were $4.0 billion, a 9 percent increase from the prior year quarter, driven by BOTOX®, JUVEDERM Collection®, the addition of ALLODERM® and CoolSculpting® and new products, including VRAYLAR™, NAMZARIC® and VIBERZI®. The increase was partially offset by lower revenues from ASACOL® HD and MINASTRIN® due to the loss of patent exclusivity, the continuing decline in NAMENDA XR® and lower revenues from RESTASIS®, which was negatively impacted by trade buying patterns in the quarter.

Read at PR Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES